drugset / Trial / NCT01764087
A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) of KX2-391 in Combination with paclitaxel in Phase I, and to evaluate the efficacy of KX2-391 in combination with paclitaxel in patients who are diagnosed as gastric and breast cancer, respectively in Phase II.
Timeline
- Start
- 2012-12
- Primary completion
- 2015-12
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tirbanibulin | Small molecule | 20 mg | Oral |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |